Evidence map›Paper›PMID 39989248›Full record

ArticleInternal medicine journal2025

Use of sodium-glucose cotransporter-2 inhibitors among Aboriginal people with type 2 diabetes in remote Northern Territory: 2012 to 2020.

Matthew J L Hare, Winnie Chen, Thomas Berhane, Sumaria M Corpus, Louise J Maple-Brown

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Matthew J L HareEndocrinology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia.ORCID 0000-0002-9364-3368
Winnie ChenWellbeing and Chronic Preventable Diseases Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.ORCID 0000-0002-3473-3080
Thomas BerhaneDivision of Medicine, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Sumaria M CorpusEndocrinology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia.
Louise J Maple-BrownEndocrinology Department, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

Funding

Australian Diabetes Society Skip Martin FellowshipDiabetes Australia Research Program Y22G-HARMNational Health and Medical Research Council, Investigator Grant 1194698Sylvia and Charles Viertel Charitable Foundation - Clinical Investigator Award
6 · The paper itself

Abstract

Aboriginal people in remote Northern Territory communities experience the highest burden of type 2 diabetes (T2D) globally. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve cardiac and renal outcomes in selected populations. However, safety in this context is unknown. We investigated SGLT2i use and outcomes in remote Aboriginal people with T2D between 2012 and 2020.

Indexed as

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsAdultAgedAustralian Aboriginal and Torres Strait Islander PeoplesFemaleHumansMaleMiddle AgedNorthern TerritorySodium-Glucose Transporter 2 Inhibitorsgeneral practiceindigenous healthpharmacoepidemiologyprimary carerural health servicetype 2 diabetes

Identifiers

PMID39989248
PMCPMC11900843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.